No Data
No Data
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
CCORF Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $26
Buy Rating on Annovis Bio Amid Progress in PD and AD Drug Development
Annovis Bio, Inc. (NYSE:ANVS) Surges 24%; Retail Investors Who Own 56% Shares Profited Along With Insiders
Maxim Group Maintains Annovis Bio(ANVS.US) With Hold Rating
Annovis Bio (ANVS) Receives a Hold From Maxim Group